Answers are grounded in this paper and cite their sources.
Real-world evidence describes treatment outcomes of carboplatin in ER/PR-negative, HER2-positive breast cancer, indicating variable clinical practices.
The role of carboplatin in ER/PR-negative, HER2-positive breast cancer remains variable in routine clinical practice, particularly in the neoadjuvant setting. Evidence from real-world cohorts describing treatment selection and associated outcomes in this molecular subtype is limited.
No takes yet. Share an insight, caveat, or question.
Suri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: